Tevogen Bio gets Nasdaq deficiency notice; must regain $1.00 bid by March 2026

Tevogen Bio Holdings Inc.

Received letter on September 23, 2025 from Nasdaq Staff for non-compliance with $1.00 minimum bid price rule.
Common stock closing bid below $1.00 for 30 consecutive business days; no immediate impact on listing.
Has 180 days (until March 23, 2026) to regain compliance by closing at $1.00+ for at least 10 consecutive days.
If not cured, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.
Company will monitor bid price and evaluate options; no assurance of regaining compliance.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.